多沙唑嗪控释片短期服用对前列腺增生症患者下尿路症状及IPSS评分的影响

目的 评价前列腺增生(BPH)患者短期(3个月)服用多沙唑嗪控释片(可多华,Cardura XL)对下尿路症状,国际前列腺症状评分(IPSS)及生活质量(QOL)的影响.方法 选择2008年7月至2009年2月在北京朝阳医院泌尿科门诊就诊的80例前列腺增生患者,患者平均年龄70.5岁(62～82岁),短期内(3个月)、前瞻性的给予多沙唑嗪控释片(4 mg/d),分别记录治疗前、治疗后1、2、3个月患者的相应临床资料:包括IPSS、QOL、最大尿流率(Qmax),残余尿,血压及心率.对治疗前后的相应数据进行配对t检验,了解药物疗效及副作用.结果 80例患者均坚持完成3个月药物治疗.对治疗前及治疗后3个月未的最大尿流率(Qmax),残余尿,IPSS(刺激评分和梗阻评分),QOL,血压及心率进行分析,结果显示除心率以外(P=0.685),其他数据配对t检验结果差异均有统计学意义(均P＜0.001),进一步对治疗后1、3个月时的IPSS和QOL进行分析,结果显示IPSS及QOL随治疗时间延长有显著性改善(P＜0.001).16例(20%)患者存在一过性药物副作用:8例(10%)患者服药初期感到头痛,4例(5%)患者感到疲倦不适,4例(5%)患者感到眩晕,无患者中途脱落.结论 前列腺增生症患者短期内服用可多华能明显改善下尿路症状及生活质量,随着服药时间延长(1～3个月),IPSS和QOL可持续性改善,患者能较好耐受药物副作用.

Clinical efficacy of a short-term regimen of Cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia

Objective To evaluate the clinical efficacy of Cardura XL (doxazosin mesylate controlled release tablets) on lower urinary tract symptoms, IPSS (international prognostic scoring system)and short-term QOL (quality of life) (3 months) in the treatment of benign prostatic hyperplasia (BPH).Methods From July 2008 to February 2009, 80 male BPH patients with a mean age of 70.5 years old(range: 62- 82 ) were prospectively recruited to receive a daily dose of Cardura XL 4 mg for 3 months.Clinical parameters of IPSS QOL, Qmax ( maximum flow rate), residual urine, blood pressure and heart ratewere recorded before and 3 months after treatment. Paired t test was performed on the corresponding data.And therapeutic efficacy and side effects were analyzed according to the statistical results. Results All 80 patients finished a 3-month medical regimen. Between pre-treatment and 3 months after medication, paired ttest was performed on the corresponding data of maximum flow rate (Qmax), residual urine, IPSS, QOL,blood pressure and heart rate. Significant differences were observed in all corresponding data( P < 0.001 )except heart rate ( P = 0.685 ). Furthermore analyses were performed on the corresponding IPSS and QOL between one month and 3 months after treatment. Significant improvementwas also observed in IPSS and QOL after a longer medication ( P < 0.001 ) . Transient side effects were observed in 16 patients (20% ):headache (n =8, 10% ), fatigue (n =4, 5% ) and dizziness (n =4, 5%). No patient withdrew from the study. Conclusion Cardura XL, at a daily dose of 4 mg daily for 3 months, is a safe and effective regimen in BPH patients. Significant improvement is observed for lower urinary tract symptoms, IPSS and QOL A longer medication may lead to further improvement of IPSS and QOL. After dosing, both systolic and diastolic blood pressures fall down significantly. No significant effect on heart rate is found. And most patients have an excellent tolerance.